Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
-
Aukið markaðsleyfi er veitt fyrir Selarsdi í Bandaríkjunum til meðferðar við Crohns- sjúkdómnum og sáraristilbólgu, sem eru þrálátir bólgusjúkdómar í meltingarvegiMatvæla- og lyfjaeftirlit...
-
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
-
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved...
-
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency...
-
Alvotech (NASDAQ: ALVO) tilkynnti í dag að Evrópska lyfjastofnunin (EMA) hafi samþykkt að taka til afgreiðslu umsókn um markaðsleyfi fyrir AVT03, fyrirhugaða líftæknilyfjahliðstæðu við Prolia og...
-
REYKJAVIK, Iceland, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
-
Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio®Sales of Entyvio (vedolizumab) were about $5.4...
-
Alvotech er einn tveggja aðila sem vitað er að hafi byrjað klíníska rannsókn á sjúklingum fyrir fyrirhugaða líftæknilyfjahliðstæðu við Entyvio (vedolizumab)Á síðustu tólf mánuðum, fram til loka...
-
Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio®Sales of Entyvio (vedolizumab) were about $5.4...